Mutated ras as a Predictor of Response:

Continuing Medical Education Information

E-Updates in Targeted Therapy in Colorectal Cancer, Volume 2: Mutated ras as a Predictor of Response: Is It Ready for the Clinic?

Activity Release Date: May 15, 2008
Activity Expiration Date: May 15, 2009

About the Activity

This activity is based on a brief article developed as part of the E-Update Series and posted on the Web. It was developed from an identified educational need for information about practical management issues in the practice of medical, surgical, and radiation oncology. This activity has been developed and approved under the direction of Beam Institute.

Activity Learning Objectives

After completing this series of activities, the clinician should be able to:

(1) Demonstrate knowledge of the phase III studies that have established a role for biologic agents in the metastatic setting, and to incorporate a game plan, tailored to the individual, using biologic agents and chemotherapy in this setting.

(2) Demonstrate knowledge of adjuvant studies of biologic agents, the biologic agents already approved in the metastatic setting, the possible use of biomarkers, and next-generation targets and agents.

(3) Apply a solid treatment strategy when dealing with toxicity issues resulting from biologic agents.

(4) Appraise the use of dual targeted therapy (EGFR and VEGF).

Target Audience

This activity targets physicians in the fields of oncology and hematology.

Accreditation

This activity has been planned and implemented in accordance with the Essential Areas and policies of the Accreditation Council for Continuing Medical Education through the joint sponsorship of Beam Institute and The Oncology Group. Beam Institute is accredited by the ACCME to provide continuing medical education for physicians.

Continuing Education Credit

AMA PRA Category 1 Credit™

Beam Institute designates this educational activity for a maximum of 2 AMA PRA Category 1 Credits™ . Physicians should only claim credit commensurate with the extent of their participation in the activity.

Compliance Statement

This activity is an independent educational activity under the direction of Beam Institute. The activity was planned and implemented in accordance with the Essential Areas and policies of the ACCME, the Ethical Opinions/Guidelines of the AMA, the FDA, the OIG, and the PhRMA Code on Interactions with Healthcare Professionals, thus assuring the highest degree of independence, fair balance, scientific rigor, and objectivity.

However, Beam Institute, the Grantor, and CMPMedica shall in no way be liable for the currency of information or for any errors, omissions, or inaccuracies in the activity. Discussions concerning drugs, dosages, and procedures may reflect the clinical experience of the author(s) or may be derived from the professional literature or other sources and may suggest uses that are investigational in nature and not approved labeling or indications. Activity participants are encouraged to refer to primary references or full prescribing information resources. The opinions and recommendations presented herein are those of the author(s) and do not necessarily reflect the views of the provider or producer.

Financial Disclosures

Dr. Marshall has acted as a speaker for, received research support from, and acted as a consultant for Roche, Sanofi, Pfizer, Genentech, Bristol-Myers Squibb, and Amgen. Dr. Venook has received research support from Genentech, Amgen, Pfizer, Novartis, and ImClone.

Copyright

Copyrights owned by Beam Institute, a division of CME LLC. Copyright © 2008, CME LLC. All rights reserved.

Contact Information

We would like to hear your comments regarding this or other activities provided by Beam Institute. In addition, suggestions for future activities are welcome. Contact us at: